Hospira Symbiq Infusion System Vulnerability
Advisory ansehen veröffentlicht 2015-03-26
This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov
01
beschreibt (1)
Zugehörige CVEs.
| ID | Schweregrad | ausnutzbar | ||
|---|---|---|---|---|
| CVE-2015-3965US | high8.8 | — | ||
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call… | ||||
02
Referenzen
Externe Belege — Patches, Meldungen, Analysen.
- ICS Advisory ICSA-15-174-01 JSONself
- Recommended Practicesexternal
- ICS Advisory ICSA-15-174-01 - Web Versionself
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
03
Behebungen (1)
- MitigationSymbiq Infusion System
Hospira has provided compensating measures to help mitigate risks associated with this vulnerability. As previously announced by Hospira in 2013, the Symbiq Infusion System would be retired on May 31, 2015, and will be fully removed from the market by December 2015.
scry
Advisories wie diese benennen die exponierten Produkte, die Angreifer auf Ihrer Angriffsfläche ins Visier nehmen. Sehen Sie mit einem kostenlosen Passiv-Scan, was exponiert ist.
Kostenloser Scan